Characteristic Study ID	Primarya endpoint (s)	Secondaryb endpoint (s)	Otherc endpoint (s)
Avilés 1999	‐	‐	Glycaemic control, insulin dose requirements, study drug tolerance, body weight, blood pressure, lipid and lipoprotein profiles, C‐peptide
Barnett 2013	Change in HbA1c from baseline to 52 weeks follow‐up	Mean change from baseline in total daily insulin dose at 52 weeks	Safety end points including adverse events, hypoglycaemia and weight gain
Casner 1988	‐	‐	Fasting blood glucose, HbA1c, C‐peptide, glucose tolerance test, side effects, compliance
Chiasson 1994	‐	‐	HbA1c, glucose, C‐peptide, lipids, glucose tolerance test, safety, blood count, biochemistry, vitamins/minerals, hypoglycaemia
Coniff 1995	HbA1c, insulin requirements	Glucose tolerance test, postprandial glucose area under the curve	Lipids, hypoglycaemia
Feinglos 19987	‐	‐	Glucose, HbA1c, C‐peptide, plasma insulin, lipids
Fonseca 2007	HbA1c	Fasting glucose, insulin dose, insulin injections, lipids, body weight	‐
Fritsche 2000	‐	‐	Glucose tolerance test, HbA1c, glucose, C‐peptide, insulin dose, lipids
Giugliano 1993	‐	‐	Body weight, blood pressure, HbA1c, lipids, glucose profile, safety
Groop 1985	‐	‐	Body weight, glucose, HbA1c, lipids, glucose tolerance test, serum free insulin, plasma glucagon, insulin tolerance test, glucose profiles
Hermann 2001	HbA1c	‐	Fasting glucose, body weight, BMI, waist‐hip ratio, blood pressure, insulin dose, C‐peptide, lipids, biochemistry, adverse events, compliance
Hong 2012	Change in HbA1c (from baseline to 24 weeks)	Proportion of participants achieving HbA1c < 7%, body weight, waist circumference, change in insulin dose, change in C‐peptide, safety (AE, SAE, hypoglycaemia, liver/renal function)	‐
Hirsch 1999	‐	‐	HbA1c, glucose, body weight, blood pressure, insulin dose, insulin levels, C‐peptide, hypoglycaemia
Kitabchi 1987	‐	‐	HbA1c, glucose, body weight, C‐peptide, insulin dose, insulin antibodies, chemistry, triglycerides
Krawczyk 2005	‐	‐	HbA1c, glucose, insulin dose, waist‐hip ratio, body weight
Kyllastinen 1985	‐	‐	Glucose, HbA1c, insulin dose, C‐peptide, body weight, biochemistry, lipids
Lewitt 1989	‐	‐	HbA1c, glucose, BMI, C‐peptide, insulin dose
Lindström 1999	‐	‐	Insulin dose, glucose, HbA1c, plasma insulin, C‐peptide, lipoproteins, IGF‐1, testosterone, SHBG
Longnecker 1986	‐	‐	HbA1c, glucose, C‐peptide, body weight, compliance, side effects
Mattoo 2005	‐	‐	HbA1c, glucose, lipids, CRP, hypoglycaemia, body weight, cardiovascular risk markers
Mauerhoff 1986	‐	‐	Glucose, C‐peptide, insulin dose, hypoglycaemia
Mezitis 1992	‐	‐	Insulin dose, C‐peptide, HbA1c, lipids, glucose profiles
Mudaliar 2010	‐	‐	HbA1c, glucose, insulin dose, weight, total body water, extracellular fluid, renal and hormonal measures
Nemoto 2011	‐	‐	Meal tolerance test, HbA1c, 1,5 AG, glycoalbumin, hypoglycaemia, safety
Osei 1984	‐	‐	Compliance, dietary intake, weight, glucose, HbA1c, tolerance tests
Quartraro 1986	‐	‐	Glucose profile, HbA1c, insulin dose, weight, C‐peptide
Reich 1987	‐	‐	HbA1c, glucose, chemistry, urinalyses
Relimpio 1998	‐	‐	Weight, BMI, blood pressure, HbA1c, lipids, insulin dose, biochemistry, compliance
Robinson 1998	‐	‐	Glucose, HbA1c, creatinine, lipids, blood pressure, insulin dose, hypoglycaemia
Rosenstock 2002	‐	‐	HbA1c, glucose, C‐peptide, lipids, ECG, chemistry, haematology, vital signs, adverse events
Schade 1987	‐	‐	HbA1c, glucose, insulin dose, C‐peptide, free insulin, erythrocyte‐glucose binding, compliance
Schiel 2007	HbA1c	Glucose, treatment satisfaction, hypoglycaemia, adverse events	Blood pressure, creatinine, liver enzymes
Simpson 1990	‐	‐	HbA1c, C‐peptide, serum insulin, lipids, glucose, body weight, BMI
Stenman 1988	‐	‐	HbA1c, glucose, body weight, lipids, C‐peptide, free insulin
Strowig 2002	‐	‐	HbA1c, glucose, liver enzymes, body weight, chemistry, C‐peptide, lipids, waist‐hip ratio
Wulffelé 2002	HbA1c, insulin dose	BMI, body weight, lipids, blood pressure	Hypoglycaemia
Yilmaz 2007	HbA1c	Insulin dose, body weight, waist‐hip ratio, lipids	Hypoglycaemia, side effects
a,bverbatim statement in the publication cnot explicitly stated as primary or secondary endpoint (s) in the publication ‐ denotes not reported BMI: body mass index; HbA1c: glycosylated haemoglobin A1c